Skip to main content

Table 1 AUROC of genomic metrics as a continuous variable

From: Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test

AUROC (95% CI)

OncoScan

n = 120

Infinium

CytoSNP-850K

n = 106

With deleterious BRCA m

LOH versus BRCAm

0.76 (0.62–0.89)

0.64 (0.46–0.82)

TAI versus BRCAm

0.78 (0.65–0.90)

0.72 (0.57–0.87)

LST versus BRCAm

0.89 (0.82–0.96)

0.83 (0.70–0.95)

HRDa versus BRCAm

0.87 (0.77–0.97)

0.75 (0.61–0.89)

With the clinically validated HRD test (cut-off, 42)

LOH versus clinically validated HRD test

0.85 (0.77–0.92)

0.78 (0.67–0.88)

TAI versus clinically validated HRD test

0.86 (0.79–0.93)

0.86 (0.78–0.93)

LST versus clinically validated HRD test

0.89 (0.82–0.95)

0.95 (0.90–0.99)

HRDa versus clinically validated HRD test

0.92 (0.87–0.97)

0.91 (0.85–0.96)

  1. aHRD is the sum of LOH, TAI, and LST
  2. Abbreviations: AUROC, area under the receiver operating characteristic; BRCAm, mutation in BRCA1, BRCA2, or both; CI, confidence interval; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale state transition; TAI, telomeric-allelic imbalance number